Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure

Circulation

Volumn 101, Issue 8, 2000, Pages 844-846

  Jorde, Ulrich P ^a   Ennezat, Pierre V ^a   Lisker, Jay ^a   Suryadevara, Vanarani ^a   Infeld, Jason ^a   Cukon, Sonja ^a   Hammer, Adam ^a   Sonnenblick, Edmund H ^a   Le Jemtel, Thierry H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin; Enzymes; Heart failure

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; VALSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; MALE; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEINASE INHIBITION; RADIAL ARTERY; SYSTOLIC BLOOD PRESSURE;

EID: 0033995775     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.8.844     Document Type: Article

References (13)

1. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari M-T, Thomas S, Le Jemtel TH. Addition of angiotension receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure Circulation. 1999;99:990-992.
2. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure Circulation. 1999;99:2658-2664.
3. Studer R, Reinecke H, Mueller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. J Clin Invest. 1994;94:301-310.
4. Wolny A, Clozel J-P, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
5. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee FJ, Maggon K, Shum L, Timmermans PBMWM, Brunner HR. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Circulation. 1991;83:1333-1342.
6. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990;15:44-55.
7. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell'Italia LJ. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol. 1996;271 (Heart Circ Physiol 40):H417-H421.
8. Muller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol. 1994;47:231-245.
9. Sassano P, Chatellier G, Billaud E, Alhenc-Gelas F, Corvol P, Menard J. Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Am J Med. 1987;83:227-235.
10. Rousseau MDF, Konstam A, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers J-M, Pouleur H. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994;73:448-493.
11. Dell'Italia LJ, Meng QC, Balcells E, Wei C-C, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angiotensin II generation in the dog heart. J Clin Invest. 1997;100:253-258.
12. Wollen KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat. Circulation. 1994;90:2457-2467.
13. Sutton MSJ, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Circulation. 1997;96:3294-3299.